首页> 外文期刊>Genes & Development >miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25A
【24h】

miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25A

机译:miR-449a和miR-449b是E2F1的直接转录靶标,并通过靶向CDK6和CDC25A的反馈环负调控pRb-E2F1的活性

获取原文
获取原文并翻译 | 示例
       

摘要

The Rb–E2F pathway drives cell cycle progression and cell proliferation, and the molecular strategies safeguarding its activity are not fully understood. Here we report that E2F1 directly transactivates miR-449a/b. miR-449a/b targets and inhibits oncogenic CDK6 and CDC25A, resulting in pRb dephosphorylation and cell cycle arrest at G1 phase, revealing a negative feedback regulation of the pRb–E2F1 pathway. Moreover, miR-449a/b expression in cancer cells is epigenetically repressed through histone H3 Lys27 trimethylation, and epigenetic drug treatment targeting histone methylation results in strong induction of miR-449a/b. Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer.
机译:Rb–E2F途径驱动细胞周期进程和细胞增殖,而保护其活性的分子策略尚不完全清楚。在这里,我们报告E2F1直接转激活miR-449a / b。 miR-449a / b靶向并抑制致癌CDK6和CDC25A,导致pRb脱磷酸化和细胞周期停滞在G1期,揭示了pRb–E2F1途径的负反馈调节。此外,癌细胞中miR-449a / b的表达通过组蛋白H3 Lys27三甲基化被表观遗传抑制,靶向组蛋白甲基化的表观遗传药物治疗导致miR-449a / b的强烈诱导。我们的研究通过调节Rb / E2F1活性揭示了miR-449a / b的抑癌功能,并暗示通过异常的表观遗传事件逃避该调节有助于人类癌症中E2F1的失控和无限制的增殖。

著录项

  • 来源
    《Genes & Development》 |2009年第20期|2388-2393|共6页
  • 作者单位

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;

    Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672|Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    CDC25A; CDK6; DZNep; E2F1; miR-449;

    机译:CDC25A;CDK6;DZNep;E2F1;miR-449;
  • 入库时间 2022-08-17 23:21:09

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号